{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:37:05Z","timestamp":1787891825191,"version":"build-2784847793"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmoop.2025.105312","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:13:26Z","timestamp":1749543206000},"page":"105312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-8015","authenticated-orcid":false,"given":"H.R.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-1963","authenticated-orcid":false,"given":"S.","family":"Lakritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-4642","authenticated-orcid":false,"given":"C.H.","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8430-1040","authenticated-orcid":false,"given":"C.J.","family":"Eule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-572X","authenticated-orcid":false,"given":"L.S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"P.","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bratslavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0105-9760","authenticated-orcid":false,"given":"D.I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-2596","authenticated-orcid":false,"given":"J.S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-3402","authenticated-orcid":false,"given":"E.T.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.esmoop.2025.105312_bib1","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1002\/cam4.1689","article-title":"Cancer of unknown primary\u2014Epidemiological trends and relevance of comprehensive genomic profiling","volume":"7","author":"Binder","year":"2018","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105312_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105312_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105312_bib4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105312_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394","article-title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105312_bib6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105312_bib7","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1002\/onco.13597","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design","volume":"26","author":"Ross","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105312_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105312_bib9","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann Oncol"},{"issue":"10452","key":"10.1016\/j.esmoop.2025.105312_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105312_bib11","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/s41467-023-42400-5","article-title":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial","volume":"14","author":"Pouyiourou","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105312_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004822","article-title":"Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial","volume":"10","author":"Raghav","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105312_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2022","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105312_bib14","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.18632\/oncotarget.2574","article-title":"Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases","volume":"5","author":"Gatalica","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2025.105312_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","article-title":"Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy","volume":"94","author":"Gatalica","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5-6","key":"10.1016\/j.esmoop.2025.105312_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.18632\/oncoscience.352","article-title":"Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape","volume":"4","author":"Subbiah","year":"2017","journal-title":"Oncoscience"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105312_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105312_bib18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105312_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105312_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105312_bib21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41698-024-00679-7","article-title":"Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab","volume":"8","author":"Lin","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105312_bib22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2020.04.012","article-title":"Comprehensive analysis of genetic ancestry and its molecular correlates in cancer","volume":"37","author":"Carrot-Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2025.105312_bib23","article-title":"Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-Ribose) polymerase inhibitor response","volume":"7","author":"Moore","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"7463","key":"10.1016\/j.esmoop.2025.105312_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105312_bib25","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-18-4159","article-title":"The genomic landscape of merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy","volume":"25","author":"Knepper","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105312_bib26","series-title":"Encyclopedia of Systems Biology","article-title":"Benjamini\u2013Hochberg method","author":"Haynes","year":"2013"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105312_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/path.2330","article-title":"The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma","volume":"215","author":"Lucas","year":"2008","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105312_bib28","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1998.16.6.2105","article-title":"Unknown primary tumors metastatic to liver","volume":"16","author":"Ayoub","year":"1998","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105312_bib29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ctrv.2008.05.005","article-title":"Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature","volume":"34","author":"Lazaridis","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105312_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","article-title":"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas","volume":"23","author":"Cappellen","year":"1999","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105312_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105312_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105312_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102035","article-title":"Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study","volume":"8","author":"Westphalen","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105312_bib34","doi-asserted-by":"crossref","first-page":"e769","DOI":"10.1002\/onco.13744","article-title":"A challenging task: identifying patients with cancer of unknown primary (CUP) according to ESMO Guidelines: the CUPISCO Trial Experience","volume":"26","author":"Pauli","year":"2021","journal-title":"Oncologist"},{"issue":"6466","key":"10.1016\/j.esmoop.2025.105312_bib35","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors","volume":"366","author":"Vasan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2025.105312_bib36","first-page":"141","article-title":"A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors","volume":"75(2)","author":"Hage Chehade","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.105312_bib37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/PO.19.00345","article-title":"Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity","volume":"4","author":"Sokol","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105312_bib38","article-title":"Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: results from the Drug Rediscovery Protocol","volume":"42","author":"Spiekman","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.105312_bib39","article-title":"Abstract CT004: KEYLYNK-007: tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency-positive advanced cancers","volume":"85","author":"Yap","year":"2025","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105312_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102041","article-title":"Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study","volume":"8","author":"Joris","year":"2023","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105312_bib41","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/2767-9764.CRC-23-0051","article-title":"Phase II window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer","volume":"3","author":"Moutafi","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"suppl 26","key":"10.1016\/j.esmoop.2025.105312_bib42","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1200\/JCO.2023.41.16_suppl.6016","article-title":"Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): a single-arm, phase 2 trial","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105312_bib43","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00405-022-07775-z","article-title":"Comparison of PD-L1 expression in squamous cell cancer of unknown primary and oropharyngeal squamous cell carcinoma","volume":"280","author":"Schmidl","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105312_bib44","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score","volume":"40","author":"Burtness","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105312_bib45","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105312_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105312_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105312_bib48","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105312_bib49","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105312_bib50","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 Is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"issue":"6278","key":"10.1016\/j.esmoop.2025.105312_bib51","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105312_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3833","article-title":"Prevalence of UV mutational signatures among cutaneous primary tumors","volume":"5","author":"Mata","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:45:05Z","timestamp":1762598705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925011810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2059702925011810"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105312","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105312"}}